Kim 2006.

Study characteristics
Methods	Randomisation: randomised, no other details Blinding: open‐label Duration: 12 weeks
Participants	Diagnosis: DSM‐IV criteria for schizophrenia N = 14 Age: 18–55 years Sex: male Setting: outpatients History: treated with a second‐generation antipsychotic for at least 8 weeks, with the same dose for at least 4 weeks; clinically stable; and to have a BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 plus adult treatment; panel III hyperlipidaemia or hypertriglyceridaemia Excluded: diagnosis of DSM‐IV substance abuse within the last month or DSM‐IV substance dependence within the last 6 months; cannabis use more than once weekly; Calgary Depression Rating Scale (CDS) total score > 7; suicidality or hospitalisation for depression in prior 6 months; the use of any medication known to alter weight or appetite; and pregnant or nursing women
Interventions	Topiramate 25 mg twice/d, increased to 50 mg twice/d. on d 8; N = 25 Control group; N = 23 Both groups on olanzapine, 10 mg/d, increasing but not to exceed 20 mg/d
Outcomes	Able to use: Primary outcome Weight measures Change in body weight Secondary outcome Mental state PANSS Adverse events Insomnia
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods not reported
Allocation concealment (selection bias)	High risk	Allocation concealment not indicated; open‐label study
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Weight outcomes unlikely to be biased by blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data were analysed in accordance with ITT methodology
Selective reporting (reporting bias)	Low risk	Primary outcome measure was reported
Other bias	Low risk	No obvious bias